{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:28:17Z","timestamp":1786987697731,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.diagmicrobio.2024.116353","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T02:26:10Z","timestamp":1715999170000},"page":"116353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study"],"prefix":"10.1016","volume":"109","author":[{"given":"Yingsha","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huidan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anyue","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lantian","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2024.116353_bib0001","unstructured":"Administration UFaD. Fact sheet for healthcare providers: emergency use authorization for paxlovid. https:\/\/www.fda.gov\/media\/155050\/download. Published 2021. Accessed 12."},{"key":"10.1016\/j.diagmicrobio.2024.116353_bib0002","unstructured":"Administration UFaD. Fact sheet for healthcare providers: emergency use authorization for Lagevriotm (molnupiravir) capsules. https:\/\/www.fda.gov\/media\/155054\/download Published 2021. Updated 12\/23. Accessed."},{"key":"10.1016\/j.diagmicrobio.2024.116353_bib0003","article-title":"Real-world effectiveness of Yindan Jiedu granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study","volume":"13","author":"Feng","year":"2022","journal-title":"Front Pharmacol"},{"issue":"10319","key":"10.1016\/j.diagmicrobio.2024.116353_bib0004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0140-6736(21)02657-X","article-title":"Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management","volume":"399","author":"Heskin","year":"2022","journal-title":"Lancet"},{"issue":"10373","key":"10.1016\/j.diagmicrobio.2024.116353_bib0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2024.116353_bib0006","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1473-3099(22)00119-0","article-title":"Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach","volume":"22","author":"Dal-R\u00e9","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2024.116353_bib0007","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1473-3099(22)00507-2","article-title":"Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study","volume":"22","author":"Wong","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2024.116353_bib0008","article-title":"The first Chinese oral anti-COVID-19 drug Azvudine launched","volume":"3","author":"Yu","year":"2022","journal-title":"Innov (Camb)"},{"issue":"10359","key":"10.1016\/j.diagmicrobio.2024.116353_bib0009","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(22)01586-0","volume":"400","author":"Wong","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2024.116353_bib0010","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1473-3099(22)00873-8","article-title":"Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study","volume":"23","author":"Wong","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2024.116353_bib0011","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/bimj.200810488","article-title":"Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations","volume":"51","author":"Austin","year":"2009","journal-title":"Biom J"},{"issue":"403","key":"10.1016\/j.diagmicrobio.2024.116353_bib0012","first-page":"569","article-title":"Locally weighted regression: an approach to regression analysis by local fitting","volume":"83","author":"Cleveland","year":"1988","journal-title":"J Am Statal Assoc"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2024.116353_bib0013","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.3346\/jkms.2022.37.e31","article-title":"Clinical characteristics of 40 patients infected with the SARS-CoV-2 omicron variant in Korea","volume":"37","author":"Kim","year":"2022","journal-title":"J Korea Med Sci"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2024.116353_bib0014","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jinf.2023.02.029","article-title":"Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute COVID-19 phase","volume":"86","author":"Wan","year":"2023","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2024.116353_bib0015","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jinf.2023.02.012","article-title":"Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study","volume":"86","author":"Evans","year":"2023","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2024.116353_bib0016","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2024.116353_bib0017","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMc2206449","article-title":"Rebound of SARS-CoV-2 infection after nirmatrelvir-ritonavir treatment","volume":"387","author":"Charness","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2024.116353_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.45086","article-title":"Incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir","volume":"5","author":"Wong","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diagmicrobio.2024.116353_bib0019","article-title":"Factors associated with viral rebound among COVID-19 patients receiving oral antivirals","author":"Chen","year":"2023","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.diagmicrobio.2024.116353_bib0020","unstructured":"Ronza N.D., Naomi G., Gabriel W., et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis. (3):3."},{"issue":"628","key":"10.1016\/j.diagmicrobio.2024.116353_bib0021","doi-asserted-by":"crossref","first-page":"eabl7430","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer","year":"2022","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2024.116353_bib0022","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.7326\/M22-0729","article-title":"Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial","volume":"175","author":"Johnson","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889324001822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889324001822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T14:29:26Z","timestamp":1719066566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889324001822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0732889324001822"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2024.116353","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4311124\/v1","asserted-by":"object"}]},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2024.116353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116353"}}